These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 33812414)

  • 1. [The Relationship between ASXL2 and ZBTB7A Gene Mutations and Prognosis in Patients with Acute Myeloid Leukemia].
    Cao HQ; Tuo JB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):450-455. PubMed ID: 33812414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.
    Kawashima N; Akashi A; Nagata Y; Kihara R; Ishikawa Y; Asou N; Ohtake S; Miyawaki S; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kitamura K; Sakaida E; Takeshita A; Suzushima H; Naoe T; Matsumura I; Miyazaki Y; Ogawa S; Kiyoi H;
    Ann Hematol; 2019 Jan; 98(1):83-91. PubMed ID: 30251205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis.
    Yamato G; Shiba N; Yoshida K; Shiraishi Y; Hara Y; Ohki K; Okubo J; Okuno H; Chiba K; Tanaka H; Kinoshita A; Moritake H; Kiyokawa N; Tomizawa D; Park MJ; Sotomatsu M; Taga T; Adachi S; Tawa A; Horibe K; Arakawa H; Miyano S; Ogawa S; Hayashi Y
    Genes Chromosomes Cancer; 2017 May; 56(5):382-393. PubMed ID: 28063196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.
    Micol JB; Duployez N; Boissel N; Petit A; Geffroy S; Nibourel O; Lacombe C; Lapillonne H; Etancelin P; Figeac M; Renneville A; Castaigne S; Leverger G; Ifrah N; Dombret H; Preudhomme C; Abdel-Wahab O; Jourdan E
    Blood; 2014 Aug; 124(9):1445-9. PubMed ID: 24973361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Frequency and clinical features of ASXL2 gene mutation in acute myeloid leukemia patients with AML1- ETO fusion gene positive].
    Zhao JX; Chen XH; Li JL; Pan J; Tan YH; Xu ZF; Ren FG; Zhang YF; Xu J; Li MQ; Li J; Zhang N; Chang JM; Wang XJ; Wang HW
    Zhonghua Xue Ye Xue Za Zhi; 2016 Aug; 37(8):676-81. PubMed ID: 27587249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relation of ASXL2 Gene Mutation with Clinical Characteristics, Prognosis and C-KIT Gene Mutation in AML Patients with AML1- ETO Fusion Gene].
    Cui P; Xu D; Xing T; Ren GH; Ma SM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):125-129. PubMed ID: 32027264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation.
    Hartmann L; Dutta S; Opatz S; Vosberg S; Reiter K; Leubolt G; Metzeler KH; Herold T; Bamopoulos SA; Bräundl K; Zellmeier E; Ksienzyk B; Konstandin NP; Schneider S; Hopfner KP; Graf A; Krebs S; Blum H; Middeke JM; Stölzel F; Thiede C; Wolf S; Bohlander SK; Preiss C; Chen-Wichmann L; Wichmann C; Sauerland MC; Büchner T; Berdel WE; Wörmann BJ; Braess J; Hiddemann W; Spiekermann K; Greif PA
    Nat Commun; 2016 Jun; 7():11733. PubMed ID: 27252013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells.
    Redondo Monte E; Wilding A; Leubolt G; Kerbs P; Bagnoli JW; Hartmann L; Hiddemann W; Chen-Wichmann L; Krebs S; Blum H; Cusan M; Vick B; Jeremias I; Enard W; Theurich S; Wichmann C; Greif PA
    Oncogene; 2020 Apr; 39(15):3195-3205. PubMed ID: 32115572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Genetic abnormalities in core binding factor acute myeloid leukemia].
    Ishikawa Y
    Rinsho Ketsueki; 2017; 58(8):991-998. PubMed ID: 28883285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature.
    Lavallée VP; Lemieux S; Boucher G; Gendron P; Boivin I; Armstrong RN; Sauvageau G; Hébert J
    Blood; 2016 May; 127(20):2498-501. PubMed ID: 26968532
    [No Abstract]   [Full Text] [Related]  

  • 11. ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.
    Micol JB; Pastore A; Inoue D; Duployez N; Kim E; Lee SC; Durham BH; Chung YR; Cho H; Zhang XJ; Yoshimi A; Krivtsov A; Koche R; Solary E; Sinha A; Preudhomme C; Abdel-Wahab O
    Nat Commun; 2017 May; 8():15429. PubMed ID: 28516957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for transcription factor ZBTB7A recognition of DNA and effects of ZBTB7A somatic mutations that occur in human acute myeloid leukemia.
    Ren R; Horton JR; Chen Q; Yang J; Liu B; Huang Y; Blumenthal RM; Zhang X; Cheng X
    J Biol Chem; 2023 Feb; 299(2):102885. PubMed ID: 36626981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The genomic landscape of core-binding factor acute myeloid leukemias.
    Faber ZJ; Chen X; Gedman AL; Boggs K; Cheng J; Ma J; Radtke I; Chao JR; Walsh MP; Song G; Andersson AK; Dang J; Dong L; Liu Y; Huether R; Cai Z; Mulder H; Wu G; Edmonson M; Rusch M; Qu C; Li Y; Vadodaria B; Wang J; Hedlund E; Cao X; Yergeau D; Nakitandwe J; Pounds SB; Shurtleff S; Fulton RS; Fulton LL; Easton J; Parganas E; Pui CH; Rubnitz JE; Ding L; Mardis ER; Wilson RK; Gruber TA; Mullighan CG; Schlenk RF; Paschka P; Döhner K; Döhner H; Bullinger L; Zhang J; Klco JM; Downing JR
    Nat Genet; 2016 Dec; 48(12):1551-1556. PubMed ID: 27798625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
    Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
    Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The impact of KIT and other concomitant gene mutations on the prognoses of patients with core-binding factor acute myeloid leukemia].
    Wang F; Wang W; Liu M; Zhang Y; Chen X; Yuan LL; Ma XL; Nie DJ; Wang MY; Zhang Y; Zhang W; Liu MY; Liu HX
    Zhonghua Yi Xue Za Zhi; 2020 Jan; 100(3):225-229. PubMed ID: 32008291
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluating the frequency, prognosis and survival of RUNX1 and ASXL1 mutations in patients with acute myeloid leukaemia in northeastern Iran.
    Parsa-Kondelaji M; Ayatollahi H; Rostami M; Sheikhi M; Barzegar F; Afzalaghaee M; Moradi E; Sadeghian MH; Momtazi-Borojeni AA
    J Cell Mol Med; 2022 Jul; 26(13):3797-3801. PubMed ID: 35692075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
    Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
    Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical features and survival analysis in non-M(3) acute myeloid leukemia patients with ASXL1 gene mutation].
    Jia WB; Liu JT; Yang XY; Wu HY; Wei YH; Can C; Wang RQ; He N; Gu CY; Ma DX; Ji CY
    Zhonghua Xue Ye Xue Za Zhi; 2022 Oct; 43(10):833-840. PubMed ID: 36709197
    [No Abstract]   [Full Text] [Related]  

  • 19. Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21).
    Duployez N; Micol JB; Boissel N; Petit A; Geffroy S; Bucci M; Lapillonne H; Renneville A; Leverger G; Ifrah N; Dombret H; Abdel-Wahab O; Jourdan E; Preudhomme C
    Leuk Lymphoma; 2016; 57(1):199-200. PubMed ID: 25856206
    [No Abstract]   [Full Text] [Related]  

  • 20. Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia.
    Fabiani E; Cicconi L; Nardozza AM; Cristiano A; Rossi M; Ottone T; Falconi G; Divona M; Testi AM; Annibali O; Castelli R; Lazarevic V; Rego E; Montesinos P; Esteve J; Venditti A; Della Porta M; Arcese W; Lo-Coco F; Voso MT
    Cancer Med; 2021 Jun; 10(12):3839-3847. PubMed ID: 34042280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.